Discovery and Validation of an Epithelial-Mesenchymal Transition-Based Signature in Gastric Cancer by Genomics and Prognosis Analysis

Table 4

Potential small compounds for treating gastric cancer based on dysregulated EMT-related genes.

Rank	CMap name	Mean		Enrichment		Specificity	Percent nonnull
1	Puromycin	0.694	4	0.929	0.00004	0.0562	100
2	Trolox C	0.461	4	0.89	0.00014	0	75
3	Cloxacillin	-0.487	4	-0.869	0.0006	0	75
4	Indoprofen	-0.307	4	-0.815	0.00213	0.0333	50
5	Diethylstilbestrol	-0.338	6	-0.663	0.00407	0.0082	50
6	Caffeic acid	0.398	3	0.853	0.00605	0	66
7	Benzamil	-0.302	6	-0.629	0.0081	0	50
8	STOCK1N-35874	-0.613	2	-0.916	0.01447	0.0331	100
9	Fasudil	-0.469	2	-0.904	0.01863	0	100
10	Amrinone	0.51	4	0.688	0.01975	0.0147	75
11	5155877	0.419	4	0.675	0.02441	0.1313	75
12	Eticlopride	-0.279	4	-0.673	0.0257	0.0758	50
13	Meropenem	0.309	4	0.668	0.02711	0.0163	50
14	16-Phenyltetranorprostaglandin E2	-0.486	4	-0.667	0.02765	0.0476	75
15	Thapsigargin	-0.496	3	-0.757	0.02934	0.2194	66
16	Pronetalol	0.265	4	0.657	0.03191	0.0089	50
17	Chloropyrazine	-0.328	4	-0.639	0.04048	0.0649	50
18	Naltrexone	-0.418	5	-0.576	0.04133	0.0899	60
19	Oxolamine	-0.355	4	-0.636	0.04255	0.1	50
20	Oxybenzone	-0.313	4	-0.635	0.04335	0.1268	50
21	Carisoprodol	-0.365	4	-0.633	0.04406	0.0248	50
22	Piperine	-0.393	4	-0.627	0.04782	0.0118	50